Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Overweight Individuals at Risk of Obesity-Related Complications
NCT07794579Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Countries
- 12
01
Overview
A Phase 3 trial of orforglipron in Overweight, sponsored by Eli Lilly and Company. Started Aug 2026; status: recruiting.
02
Drugs
orforglipron
03
Conditions
Overweight
Beyond the preview
Go deeper on NCT07794579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794579.